PURPOSE: To evaluate whether the in vitro incubation of spermatozoa with myoinositol may improve the fertilization rate in ICSI cycles. METHODS: This is a prospective, bicentric, randomized study on 500 MII sibling oocytes injected in 78 ICSI cycles performed between March and October 2013. Randomization of the oocytes into two groups was performed at the time of the denudation. Fertilization rates (per oocyte injected with spermatozoa treated with myoinositol versus per oocyte injected with spermatozoa treated with placebo) were measured as primary outcome and embryo morphology as secondary outcome. Clinical outcomes were also documented. RESULT (S): Fertilization rate (78.9 ± 28.6% vs 63.2 ± 36.7, P = 0.002) and percentage of grade A embryos on day 3 (59.8 ± 35.6% vs 43.5 ± 41.5, P = 0.019) were significantly higher when spermatozoa were treated in vitro with myoinositol versus placebo. No differences were found for the expanded blastocyst formation rate. CONCLUSION (S): In vitro treatment of spermatozoa with myoinositol may optimize ICSI outcomes by improving the fertilization rate and embryo quality on day 3. The improvement of the number and the quality of embryos available in an ICSI cycle may have clinical utility if these findings can be confirmed.
PURPOSE: To evaluate whether the in vitro incubation of spermatozoa with myoinositol may improve the fertilization rate in ICSI cycles. METHODS: This is a prospective, bicentric, randomized study on 500 MII sibling oocytes injected in 78 ICSI cycles performed between March and October 2013. Randomization of the oocytes into two groups was performed at the time of the denudation. Fertilization rates (per oocyte injected with spermatozoa treated with myoinositol versus per oocyte injected with spermatozoa treated with placebo) were measured as primary outcome and embryo morphology as secondary outcome. Clinical outcomes were also documented. RESULT (S): Fertilization rate (78.9 ± 28.6% vs 63.2 ± 36.7, P = 0.002) and percentage of grade A embryos on day 3 (59.8 ± 35.6% vs 43.5 ± 41.5, P = 0.019) were significantly higher when spermatozoa were treated in vitro with myoinositol versus placebo. No differences were found for the expanded blastocyst formation rate. CONCLUSION (S): In vitro treatment of spermatozoa with myoinositol may optimize ICSI outcomes by improving the fertilization rate and embryo quality on day 3. The improvement of the number and the quality of embryos available in an ICSI cycle may have clinical utility if these findings can be confirmed.
Authors: Michael O'Connell; Neil McClure; Lesley A Powell; E Kristine Steele; Sheena E M Lewis Journal: Fertil Steril Date: 2003-03 Impact factor: 7.329
Authors: S Naaby-Hansen; M J Wolkowicz; K Klotz; L A Bush; V A Westbrook; H Shibahara; J Shetty; S A Coonrod; P P Reddi; J Shannon; M Kinter; N E Sherman; J Fox; C J Flickinger; J C Herr Journal: Mol Hum Reprod Date: 2001-10 Impact factor: 4.025
Authors: Wardah Alasmari; Christopher L R Barratt; Stephen J Publicover; Katherine M Whalley; Erica Foster; Vanessa Kay; Sarah Martins da Silva; Senga K Oxenham Journal: Hum Reprod Date: 2013-02-12 Impact factor: 6.918
Authors: Simona Dinicola; Vittorio Unfer; Fabio Facchinetti; Christophe O Soulage; Nicholas D Greene; Mariano Bizzarri; Antonio Simone Laganà; Shiao-Yng Chan; Arturo Bevilacqua; Lali Pkhaladze; Salvatore Benvenga; Annarita Stringaro; Daniele Barbaro; Marialuisa Appetecchia; Cesare Aragona; Maria Salomè Bezerra Espinola; Tonino Cantelmi; Pietro Cavalli; Tony T Chiu; Andrew J Copp; Rosario D'Anna; Didier Dewailly; Cherubino Di Lorenzo; Evanthia Diamanti-Kandarakis; Imelda Hernández Marín; Moshe Hod; Zdravko Kamenov; Eleni Kandaraki; Giovanni Monastra; Mario Montanino Oliva; John E Nestler; Maurizio Nordio; Ali C Ozay; Olga Papalou; Giuseppina Porcaro; Nikos Prapas; Scott Roseff; Monica Vazquez-Levin; Ivana Vucenik; Artur Wdowiak Journal: Int J Mol Sci Date: 2021-09-30 Impact factor: 5.923
Authors: Federica Barbagallo; Sandro La Vignera; Rossella Cannarella; Antonio Aversa; Aldo E Calogero; Rosita A Condorelli Journal: J Clin Med Date: 2020-01-29 Impact factor: 4.241